Document
DailyMed Label: Flector
Title
DailyMed Label: Flector
Date
2010
Document type
DailyMed Prescription
Name
Flector
Generic name
Diclofenac Epolamine
Manufacturer
Physicians Total Care, Inc.
Product information
NDC: 54868-5962
Product information
NDC: 54868-5962
Description
Flector® Patch (10 cm x 14 cm) is comprised of an adhesive
material containing 1.3% diclofenac epolamine which is applied to a non-woven
polyester felt backing and covered with a polypropylene film release liner. The
release liner is removed prior to topical application to the skin.
Diclofenac epolamine is a non-opioid analgesic chemically designated as
2-[(2,6-dichlorophenyl) amino]benzeneacetic acid, (2-(pyrrolidin-1-yl) ethanol
salt, with a molecular formula of C 20 H 24 C l2 N 2 O 3 (molecular weight 411.3), an n-octanol/water partition
coefficient of 8 at pH 8.5, and the following structure:
Each adhesive patch contains 180 mg of diclofenac epolamine (13 mg per gram
adhesive) in an aqueous base. It also contains the following inactive
ingredients: 1,3-butylene glycol, dihydroxyaluminum aminoacetate, disodium
edetate, D-sorbitol, fragrance (Dalin PH), gelatin, kaolin, methylparaben,
polysorbate 80, povidone, propylene glycol, propylparaben, sodium
carboxymethylcellulose, sodium polyacrylate, tartaric acid, titanium dioxide,
and purified water.
image of chemical structure
Indications
Carefully consider the potential benefits and risks of Flector®
Patch and other treatment options before deciding to use Flector® Patch. Use the
lowest effective dose for the shortest duration consistent with individual
patient treatment goals (see
WARNINGS
).
Flector® Patch is indicated for the topical treatment of acute pain due to
minor strains, sprains, and contusions.
Dosage
Carefully consider the potential benefits and risks of Flector®
Patch and other treatment options before deciding to use Flector® Patch. Use
the lowest effective dose for the shortest duration consistent with individual
patient treatment goals (see
WARNINGS
).
The recommended dose of Flector® Patch is one (1) patch to the most painful
area twice a day.
Flector® patch should not be applied to damaged or non-intact skin.
Flector® patch should not be worn when bathing or showering.
Contraindications
Flector® Patch is contraindicated in patients with known
hypersensitivity to diclofenac.
Flector® Patch should not be given to patients who have experienced asthma,
urticaria, or allergic-type reactions after taking aspirin or other NSAIDs.
Severe, rarely fatal, anaphylactic-like reactions to NSAIDs have been reported
in such patients (see
WARNINGS - Anaphylactoid
Reactions
, and
PRECAUTIONS - Preexisting
Asthma
).
Flector® Patch is contraindicated for the treatment of peri-operative pain in
the setting of coronary artery bypass graft (CABG) surgery (see
WARNINGS
).
Flector® Patch should not be applied to non-intact or damaged skin resulting
from any etiology e.g. exudative dermatitis, eczema, infected lesion, burns or
wounds.
Precautions
General Flector® Patch cannot be expected to substitute for
corticosteroids or to treat corticosteroid insufficiency. Abrupt discontinuation
of corticosteroids may lead to disease exacerbation. Patients on prolonged
corticosteroid therapy should have their therapy tapered slowly if a decision is
made to discontinue corticosteroids.
The pharmacological activity of Flector® Patch in reducing inflammation may
diminish the utility of these diagnostic signs in detecting complications of
presumed noninfectious, painful conditions.
Hepatic Effects Borderline elevations of one or more liver tests may occur in up
to 15% of patients taking NSAIDs including Flector® Patch. These laboratory
abnormalities may progress, may remain unchanged, or may be transient with
continuing therapy. Notable elevations of ALT or AST (approximately three or
more times the upper limit of normal) have been reported in approximately 1% of
patients in clinical trials with NSAIDs. In addition, rare cases of severe
hepatic reactions, including jaundice and fatal fulminant hepatitis, liver
necrosis and hepatic failure, some of them with fatal outcomes have been
reported.
A patient with symptoms and/or signs suggesting liver dysfunction, or in whom
an abnormal liver test has occurred, should be evaluated for evidence of the
development of a more severe hepatic reaction while on therapy with Flector®
Patch. If clinical signs and symptoms consistent with liver disease develop, or
if systemic manifestations occur (e.g., eosinophilia, rash, etc.), Flector®
Patch should be discontinued.
Hematological Effects Anemia is sometimes seen in patients receiving NSAIDs. This may
be due to fluid retention, occult or gross GI blood loss, or an incompletely
described effect upon erythropoiesis. Patients on long-term treatment with
NSAIDs, including Flector® Patch, should have their hemoglobin or hematocrit
checked if they exhibit any signs or symptoms of anemia.
NSAIDs inhibit platelet aggregation and have been shown to prolong bleeding
time in some patients. Unlike aspirin, their effect on platelet function is
quantitatively less, of shorter duration, and reversible. Patients receiving
Flector® Patch who may be adversely affected by alterations in platelet
function, such as those with coagulation disorders or patients receiving
anticoagulants, should be carefully monitored.
Preexisting Asthma Patients with asthma may have aspirin-sensitive asthma. The use
of aspirin in patients with aspirin-sensitive asthma has been associated with
severe bronchospasm which can be fatal. Since cross reactivity, including
bronchospasm, between aspirin and other nonsteroidal anti-inflammatory drugs has
been reported in such aspirin-sensitive patients, Flector® Patch should not be
administered to patients with this form of aspirin sensitivity and should be
used with caution in patients with preexisting asthma.
Eye Exposure Contact of Flector® Patch with eyes and mucosa, although not
studied, should be avoided. If eye contact occurs, immediately wash out the eye
with water or saline. Consult a physician if irritation persists for more than
an hour.
Accidental Exposure in Children Even a used Flector® Patch contains a large amount of diclofenac
epolamine (as much as 170 mg). The potential therefore exists for a small child
or pet to suffer serious adverse effects from chewing or ingesting a new or used
Flector® Patch. It is important for patients to store and dispose of Flector®
Patch out of the reach of children and pets.
Information for Patients
Patients should be informed of the following
information before initiating therapy with an NSAID and periodically during the
course of ongoing therapy. Patients should also be encouraged to read the NSAID
Medication Guide that accompanies each prescription dispensed.
Flector® Patch, like other NSAIDs, may cause serious CV side
effects, such as MI or stroke, which may result in hospitalization and even
death. Although serious CV events can occur without warning symptoms, patients
should be alert for the signs and symptoms of chest pain, shortness of breath,
weakness, slurring of speech, and should ask for medical advice when observing
any indicative sign or symptoms. Patients should be apprised of the importance
of this follow-up (see
WARNINGS, Cardiovascular
Effects
).
Flector® Patch, like other NSAIDs, may cause GI discomfort and,
rarely, serious GI side effects, such as ulcers and bleeding, which may result
in hospitalization and even death. Although serious GI tract ulcerations and
bleeding can occur without warning symptoms, patients should be alert for the
signs and symptoms of ulcerations and bleeding, and should ask for medical
advice when observing any indicative sign or symptoms including epigastric pain,
dyspepsia, melena, and hematemesis. Patients should be apprised of the
importance of this follow-up (see
WARNINGS, Gastrointestinal
Effects: Risk of Ulceration, Bleeding, and Perforation
).
Flector® Patch, like other NSAIDs, may cause serious skin side
effects such as exfoliative dermatitis, SJS, and TEN, which may result in
hospitalizations and even death. Although serious skin reactions may occur
without warning, patients should be alert for the signs and symptoms of skin
rash and blisters, fever, or other signs of hypersensitivity such as itching,
and should ask for medical advice when observing any indicative signs or
symptoms. Patients should be advised to stop the drug immediately if they
develop any type of rash and contact their physicians as soon as
possible.
Patients should be instructed to promptly report signs or
symptoms of unexplained weight gain or edema to their physicians (see
WARNINGS,
Cardiovascular Effects
).
Patients should be informed of the warning signs and symptoms of
hepatotoxicity (e.g., nausea, fatigue, lethargy, pruritus, jaundice, right upper
quadrant tenderness, and "flu-like" symptoms). If these occur, patients should
be instructed to stop therapy and seek immediate medical therapy.
Patients should be informed of the signs of an anaphylactoid
reaction (e.g. difficulty breathing, swelling of the face or throat). If these
occur, patients should be instructed to seek immediate emergency help (see
WARNINGS
).
In late pregnancy, as with other NSAIDs, Flector® Patch should be
avoided because it may cause premature closure of the ductus
arteriosus.
Patients should be advised not to use Flector® Patch if they have
a aspirin-sensitive asthma. Flector® Patch, like other NSAIDs, could cause
severe and even fatal bronchospasm in these patients (see
PRECAUTIONS, Preexisting
asthma
). Patients should discontinue use of Flector® Patch and
should immediately seek emergency help if they experience wheezing or shortness
of breath.
Patients should be informed that Flector® Patch should be used
only on intact skin.
Patients should be advised to avoid contact of Flector® Patch
with eyes and mucosa. Patients should be instructed that if eye contact occurs,
they should immediately wash out the eye with water or saline, and consult a
physician if irritation persists for more than an hour.
Patients and caregivers should be instructed to wash their hands
after applying, handling or removing the patch.
Patients should be informed that, if Flector® Patch begins to
peel off, the edges of the patch may be taped down.
Patients should be instructed not to wear Flector® Patch during
bathing or showering. Bathing should take place in between scheduled patch
removal and application (see
DOSAGE AND
ADMINISTRATION
).
Patients should be advised to store Flector® Patch and to discard
used patches out of the reach of children and pets. If a child or pet
accidentally ingests Flector® Patch, medical help should be sought immediately
(see
PRECAUTIONS, Accidental
Exposure in Children
).
Laboratory Tests Because serious GI tract ulcerations and bleeding can occur
without warning symptoms, physicians should monitor for signs or symptoms of GI
bleeding. Patients on long-term treatment with NSAIDs, should have their CBC
and a chemistry profile checked periodically. If clinical signs and symptoms
consistent with liver or renal disease develop, systemic manifestations occur
(e.g., eosinophilia, rash, etc.) or if abnormal liver tests persist or worsen,
Flector® Patch should be discontinued.
Drug Interactions
ACE-inhibitors
Reports suggest that NSAIDs may diminish the antihypertensive effect of
ACE-inhibitors. This interaction should be given consideration in patients
taking NSAIDs concomitantly with ACE-inhibitors.
Aspirin
When Flector® Patch is administered with aspirin, the binding of diclofenac
to protein is reduced, although the clearance of free diclofenac is not altered.
The clinical significance of this interaction is not known; however, as with
other NSAIDs, concomitant administration of diclofenac and aspirin is not
generally recommended because of the potential of increased adverse effects.
Diuretics
Clinical studies, as well as post marketing observations, have shown that
Flector® Patch may reduce the natriuretic effect-of furosemide and thiazides in
some patients. This response has been attributed to inhibition of renal
prostaglandin synthesis. During concomitant therapy with NSAIDs, the patient
should be observed closely for signs of renal failure (see
WARNINGS, Renal
Effects
), as well as to assure diuretic efficacy.
Lithium
NSAIDs have produced an elevation of plasma lithium levels and a reduction in
renal lithium clearance. The mean minimum lithium concentration increased 15%
and the renal clearance was decreased by approximately 20%. These effects have
been attributed to inhibition of renal prostaglandin synthesis by the NSAID.
Thus, when NSAIDs and lithium are administered concurrently, subjects should be
observed carefully for signs of lithium toxicity.
Methotrexate
NSAIDs have been reported to competitively inhibit methotrexate accumulation
in rabbit kidney slices. This may indicate that they could enhance the toxicity
of methotrexate. Caution should be used when NSAIDs are administered
concomitantly with methotrexate.
Warfarin
The effects of warfarin and NSAIDs on GI bleeding are synergistic, such that
users of both drugs together have a risk of serious GI bleeding higher than
users of either drug alone.
Carcinogenesis, Mutagenesis, Impairment of
Fertility
Carcinogenesis
Long-term studies in animals have not been performed to evaluate the
carcinogenic potential of either diclofenac epolamine or Flector Patch.
Mutagenesis
Diclofenac epolamine is not mutagenic in Salmonella
Typhimurium strains, nor does it induce an increase in metabolic
aberrations in cultured human lymphocytes, or the frequency of micronucleated
cells in the bone marrow micronucleus test performed in rats.
Impairment of Fertility
Male and female Sprague Dawley rats were administered 1, 3, or 6 mg/kg/day
diclofenac epolamine via oral gavage (males treated for 60 days prior to
conception and during mating period, females treated for 14 days prior to mating
through day 19 of gestation). Diclofenac epolamine treatment with 6 mg/kg/day
resulted in increased early resorptions and postimplantation losses; however, no
effects on the mating and fertility indices were found. The 6 mg/kg/day dose
corresponds to 3-times the maximum recommended daily exposure in humans based on
a body surface area comparison.
Pregnancy
Teratogenic Effects Pregnancy Category C. Pregnant Sprague Dawley rats were administered 1, 3, or 6 mg/kg
diclofenac epolamine via oral gavage daily from gestation days 6-15. Maternal
toxicity, embryotoxicity, and increased incidence of skeletal anomalies were
noted with 6 mg/kg/day diclofenac epolamine, which corresponds to 3-times the
maximum recommended daily exposure in humans based on a body surface area
comparison. Pregnant New Zealand White rabbits were administered 1, 3, or 6
mg/kg diclofenac epolamine vial oral gavage daily from gestation days 6-18. No
maternal toxicity was noted; however, embryotoxicity was evident at 6 mg/kg/day
group which corresponds to 6.5-times the maximum recommended daily exposure in
humans based on a body surface area comparison.
There are no adequate and well-controlled studies in pregnant women. Flector
Patch should be used during pregnancy only if the potential benefit justifies
the potential risk to the fetus.
Nonteratogenic Effects Because of the known effects of nonsteroidal anti-inflammatory
drugs on the fetal cardiovascular system (closure of ductus arteriosus), use
during pregnancy (particularly late pregnancy) should be avoided.
Male rats were orally administered diclofenac epolamine (1, 3, 6 mg/kg) for
60 days prior to mating and throughout the mating period, and females were given
the same doses 14 days prior to mating and through mating, gestation, and
lactation. Embryotoxicity was observed at 6 mg/kg diclofenac epolamine (3-times
the maximum recommended daily exposure in humans based on a body surface area
comparison), and was manifested as an increase in early resorptions,
post-implantation losses, and a decrease in live fetuses. The number of live
born and total born were also reduced as was F1 postnatal survival, but the
physical and behavioral development of surviving F1 pups in all groups was the
same as the deionized water control, nor was reproductive performance adversely
affected despite a slight treatment-related reduction in body weight.
Labor and Delivery In rat studies with NSAIDs, as with other drugs known to inhibit
prostaglandin synthesis, an increased incidence of dystocia, delayed
parturition, and decreased pup survival occurred. The effects of Flector® Patch
on labor and delivery in pregnant women are unknown.
Nursing Mothers It is not known whether this drug is excreted in human milk.
Because many drugs are excreted in human-milk and because of the potential for
serious adverse reactions in nursing infants from Flector® Patch, a decision
should be made whether to discontinue nursing or to discontinue the drug, taking
into account the importance of the drug to the mother.
Pediatric Use Safety and effectiveness in pediatric patients have not been
established.
Geriatric Use Clinical studies of Flector® Patch did not include sufficient
numbers of subjects aged 65 and over to determine whether they respond
differently from younger subjects. Other reported clinical experience has not
identified differences in responses between the elderly and younger
patients.
Diclofenac, as with any NSAID, is known to be substantially excreted by the
kidney, and the risk of toxic reactions to Flector® Patch may be greater in
patients with impaired renal function. Because elderly patients are more likely
to have decreased renal function, care should be taken when using Flector® Patch
in the elderly, and it may be useful to monitor renal function.
Adverse reactions
In controlled trials during the premarketing development of
Flector® Patch, approximately 600 patients with minor sprains, strains, and
contusions have been treated with Flector® Patch for up to two weeks.
How supplied
The Flector® Patch is supplied in resealable envelopes, each
containing 5 patches (10 cm x 14 cm), with 6 envelopes per
box ( NDC 54868-5962-0 ). Each individual patch is embossed with “Diclofenac
Epolamine Patch 1.3%”.
Each patch contains 180 mg of diclofenac epolamine in an aqueous
base (13 mg of active per gram of adhesive or 1.3%).
The product is intended for topical use only
Keep out of reach of children and pets.
The ENVELOPES SHOULD BE SEALED AT ALL TIMES WHEN NOT IN
USE.
Store at 25ºC (77ºF); excursions permitted to 15º-30ºC
(59º-86ºF). [See USP Controlled Room Temperature].
Manufacturer : Teikoku Seiyaku Co., Ltd., Sanbonmatsu, Kagawa 769-2695,
Japan
Distributor : Alpharma Pharmaceuticals LLC, One New England Avenue,
Piscataway, NJ 08854 (Telephone: 1-877-452-3426)
Version June 2008 8283 Ed II/06.08
Relabeling of "Additional Barcode" by Physicians Total Care, Inc. Tulsa, OK 74146
Clinical pharmacology
Pharmacodynamics Flector® Patch applied to intact skin provides local analgesia by
releasing diclofenac epolamine from the patch into the skin. Diclofenac is a
nonsteroidal anti-inflammatory drug (NSAID). In pharmacologic studies,
diclofenac has shown anti-inflammatory, analgesic, and antipyretic activity. As
with other NSAIDs, its mode of action is not known; its ability to inhibit
prostaglandin synthesis, however, may be involved in its anti-inflammatory
activity, as well as contribute to its efficacy in relieving pain associated
with inflammation.
Pharmacokinetics
Absorption
Following a single application of the Flector Patch on the upper inner arm,
peak plasma concentrations of diclofenac (range 0.7 – 6 ng/mL) were noted
between 10 – 20 hours of application. Plasma concentrations of diclofenac in
the range of 1.3 – 8.8 ng/mL were noted after five days with twice-a-day Flector
Patch application.
Systemic exposure (AUC) and maximum plasma concentrations of diclofenac,
after repeated dosing for four days with Flector® Patch, were lower (less than 1%)
than after a single oral 50 mg diclofenac sodium tablet.
The pharmacokinetics of Flector® Patch has been tested in healthy volunteers
at rest or undergoing moderate exercise (cycling 20 min/h for 12 h at a mean HR
of 100.3 bpm). No clinically relevant differences in systemic absorption were
observed, with peak plasma concentrations in the range of 2.2 – 8.1 ng/m while
resting, and 2.7 – 7.2 ng/mL during exercise.
Distribution
Diclofenac has a very high affinity (greater than 99%) for human serum albumin.
Metabolism and Excretion
The plasma elimination half-life of diclofenac after application of Flector
Patch is approximately 12 hours. Diclofenac is eliminated through metabolism
and subsequent urinary and biliary excretion of the glucuronide and the sulfate
conjugates of the metabolites.
Clinical studies
Efficacy of Flector® Patch was demonstrated in two of four studies of patients
with minor sprains, strains, and contusions. Patients were randomly assigned to
treatment with the Flector® Patch, or a placebo patch identical to the Flector®
Patch minus the active ingredient. In the first of these two studies, patients
with ankle sprains were treated once daily for a week. In the second study,
patients with sprains, strains and contusions were treated twice daily for up to
two weeks. Pain was assessed over the period of treatment. Patients treated
with the Flector® Patch experienced a greater reduction in pain as compared to
patients randomized to placebo patch as evidenced by the responder curves
presented below.
image of figure 1
image of figure 2
image of figure 3
image of figure 4
Package label
Flector® Patch
(diclofenac epolamine topical patch)
1.3%
image of package label
3 organizations
1 product
Product
LicartOrganization
Rebel Distributors Corp.Organization
IBSA Pharma Inc.Organization
Physicians Total Care, Inc.